Ban Tom

Researchers are evaluating the safety and immune system effects of Spirulina Blue Protein capsules in healthy adults aged 25 to 60 years. This randomized, double-blind, placebo-controlled trial aims to better understand the potential immune benefits and safety of Spirulina Blue Protein, which has shown antioxidant, anti-inflammatory, and immune-modulating effects in preclinical studies but lacks sufficient human evidence. Participants will be randomly assigned to one of three groups placebo, 200 mgday Spirulina Blue Protein, or 1,000 mgday Spirulina Blue Protein capsules taken orally once daily for 12 weeks. The study will compare these groups to assess immune cell changes and cytokine levels, with interventions delivered in a parallel design over the 12-week period. During the study, participants will undergo blood sampling before and after treatment to measure immune cells like CD4, CD8, and natural killer cells, as well as cytokines such as IL-2, IL-6, IFN-, and TNF-. Safety will be monitored through vital signs, blood counts, liver and kidney tests, and tracking of any adverse events. The total participation time includes the 12-week treatment and assessments to evaluate immune function and tolerability.

Researchers are evaluating whether a higher dose of cetirizine provides better relief than the standard dose for adults with acute urticaria, a condition causing sudden itchy wheals. This clinical trial aims to understand if increasing cetirizine to 40 mg daily improves symptoms faster and is safe over a short period. The study also explores side effects and helps reduce unnecessary steroid use in treating this condition. Participants are randomly assigned to one of two groups one taking the standard 10 mg dose once daily, and the other taking a higher 40 mg dose split into two 20 mg capsules daily. Both groups take their assigned medication for 7 days, recording their daily symptoms. Follow-up visits occur on Day 3, Day 7, and Week 6 to assess symptom improvement and safety. The study uses capsules that look identical to maintain fairness. Before and after treatment, participants have blood tests to check liver and kidney function. Researchers monitor symptoms using validated tools and track the need for rescue medications like corticosteroids. The main outcomes focus on how quickly symptoms resolve and changes in urticaria activity. The study lasts through the follow-up at Week 6 to observe longer-term effects and any recurrence of symptoms.

Researchers are evaluating doravirine as an alternative to dolutegravir in people newly diagnosed with HIV-1 infection who have not yet received treatment. This Phase III, open-label, randomized clinical trial aims to determine if doravirine combined with tenofovir and lamivudine is not less effective than dolutegravir combined with tenofovir and lamivudine or emtricitabine. The study will be conducted across multiple countries including Brazil, Cameroon, Cte dIvoire, France, Mozambique, and Thailand, enrolling 610 participants. Participants will be randomly assigned to one of two groups one receiving doravirine 100 mg plus tenofovir DF 300 mg and lamivudine 300 mg daily, and the other receiving dolutegravir 50 mg plus tenofovir DF 300 mg and either lamivudine or emtricitabine daily. The treatment period will last for 96 weeks after starting antiretroviral therapy ART, with primary assessment at week 48 to measure viral suppression. During the study, participants will undergo evaluations to monitor viral load, drug resistance, metabolic health, body weight changes, liver and kidney function, cardiovascular status, and mental health. Adherence to ART will be tracked, and blood samples will be taken to measure drug levels and immune cell counts. The research team will review virological efficacy and safety outcomes at weeks 48 and 96, supporting a comprehensive understanding of the treatments effects over nearly two years of participation.